On this page
COMMITTEE ACTION:
SF 3050 – Controlled Substance Schedules
SF 3050relates to
controlled substances. It allows the Pharmacy Board to change the schedule
status of cannabis-derived products and cannabis-derived investigational
products based on decisions of the Food and Drug Administration and the Federal
Drug Enforcement Administration. The bill classifies nine synthetic opioids,
one opioid analgesic, 10 synthetic cannabinoids and seven synthetic cathinones
as Schedule I substances, meaning they have no known medical use. It classifies
all products containing derivatives of barbituric acid as Schedule II. It
classifies one central nervous system depressant and one central nervous system
stimulant as Schedule IV, and any FDA-approved product containing cannabidiol with
no more than 0.1 percent THC as Schedule V. The bill also strikes language
regarding medical marijuana programs at the Board of Pharmacy.
[1/29: short form (Excused: Carlin)]
SSB 3051 – Prescription Monitoring Program
SSB 3051allows
veterinarians to register for and access information from the state’s Prescription
Monitoring Program. Some veterinarians can prescribe controlled substances, and
instances of pet owners taking the animal’s medication have happened. The bill
also expands PMP reporting requirements to all Schedule III and IV controlled
substances and to all Schedule V controlled substances except pseudoephedrine. Additional
substances that the PMP Advisory Council and Board of Pharmacy determine could
be addictive or fatal are also included in the required PMP reporting. The due
date for the PMP annual reports is changed to February 1, instead of January 1.
[1/29: short form (Excused: Carlin)]